Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.
View Top Employees from AdimabWebsite | http://www.adimab.com |
Revenue | $23 million |
Funding | $32 million |
Employees | 159 (159 on RocketReach) |
Founded | 2007 |
Address | 7 Lucent Drive, Lebanon, New Hampshire 03784, US |
Phone | (603) 653-5775 |
Fax | (866) 786-9819 |
Technologies |
JavaScript,
HTML,
Twitter
+22 more
(view full list)
|
Industry | Business Services, Biotechnology Research, Biotechnology, Human antibody discovery, Science and Engineering, Collaboration, Therapeutics, Health Care |
Web Rank | 4 Million |
Keywords | Cars, Biotechnology |
Competitors | AbCellera, Alector, AnaptysBio, PharmAbcine Inc., XBiotech USA, Inc. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular Adimab employee's phone or email?
The Adimab annual revenue was $23 million in 2024.
Philip Chase is the CEO of Adimab.
159 people are employed at Adimab.
Adimab is based in Lebanon, New Hampshire.
The NAICS codes for Adimab are [541714, 5417, 54171, 541, 54].
The SIC codes for Adimab are [87, 873].